Publications

• Host absence of CCR5 potentiates dendritic cell vaccination.
  April 15, 2005
  Ng-Cashin J, Kuhns JJ, Burkett SE, Powderly JD, Craven RR, van Deventer HW, Kirby SL, Serody JS.
  
  
  
• Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice.
  May 1, 2003
  Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR.
  
  
  
• Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors.
  August 1, 2002.
  van Deventer HW, Serody JS, McKinnon KP, Clements C, Brickey WJ, Ting JP.
  
  
  
• T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.
  November 1, 2000.
  Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR.
  
  
  
• Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation.
  September 26, 2000.
  Serody JS, Berrey MM, Albritton K, O'Brien SM, Capel EP, Bigelow SH, Weber DJ, Gabriel , Wiley JM, Schell MJ, Gilligan PH, Shea TC.
  
  
  
• Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation.
  June, 2000.
  Serody JS, Sparks SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL, Gabriel DA, Wiley JM, Brecher ME, Schell MJ, Folds J, Shea TC.
  
  
  
• 
  May 1, 2000.
  Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA.
  
  
  
• CD8+ T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo.
  May 1, 1999.
  Cook DN, Smithies O, Strieter RM, Frelinger JA, Serody JS.
  
  
  
• Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier.
  January 1, 1999.
  Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA.
  
  
  
• Immune response of beta 2-microglobulin-deficient mice to pathogens.
  1998.
  Frelinger JA, Serody J.
  
  
  
• Prevention of infections in bone marrow transplant recipients.
  June 1997.
  Serody JS, Shea TC.
  
  
  
• A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes.
  April 15, 1997
  Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC.
  
  
  
• Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
  March 19, 1997.
  Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC.
  
  
• CD4+ cytolytic effectors are inefficient in the clearance of Listeria monocytogenes.
  August, 1996.
  Serody JS, Poston RM, Weinstock D, Kurlander RJ, Frelinger JA.
  
  
  
• Thrombocytopenia in allogeneic peripheral blood stem cell collections.
  July 1996.
  Bandarenko N, Brecher ME, Owen H, Wiley J, Shea T, Serody J.
  
  
  
• Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.
  October 1995.
  Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, Washburn RG.
  
  
  
• A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
  October 1995.
  Shea T, Graham M, Bernard S, Steagall A, Wiley J, Serody J, Brecher M, Bentley S, Johnston C, Vaisman A, et al.
  
  
  
• The role of lactoferrin as an anti-inflammatory molecule.
  1994.
  Britigan BE, Serody JS, Cohen MS.
  
  
  
• Blastomycosis in transplant recipients: report of a case and review.
  January 1993
  Serody JS, Mill MR, Detterbeck FC, Harris DT, Cohen MS.
  
  
• Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation.
  December 1996.
  Cohen MS, Mao J, Rasmussen GT, Serody JS, Britigan BE.
  
  
• Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation.
  December 15, 1991.
  Britigan BE, Serody JS, Hayek MB, Charniga LM, Cohen MS.